Wishlist (0)
Welcome visitor Login or Register.
My Cart    0 $0.00
Your shopping cart is empty!
PD0325901

PD0325901

0 reviews Write a review
Product Code: 3315
Availability: In Stock
$146.00
-+

PD0325901 (PD325901) is selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 1/2.

Chemical Name (R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide

Inhibitors MAPK MEK PD0325901 391210-10-9
Biological Activity:
Biological Activity PD0325901 (PD325901) is selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 1/2.
Technical Data:
M.W. 482.19
Formula: <p>C<sub>16</sub>H<sub>14</sub>F<sub>3</sub>IN<sub>2</sub>O<sub>4</sub></p>
Solubility: DMSO
Purity: 98%
Storage: -20℃
CAS No: 391210-10-9
References:
References Barrett SD, et al. Bioorg Med Chem Lett, 2008, 18(24), 6501-6504. Judith SS, et al. Proc Amer Assoc Cancer Res.2004,45, Abstract #4003 Henderson YC, et al. Mol Cancer Ther, 2010, 9(7), 1968-1976. Paterson A, et al. Blood, 2012, 119(7), 1726-1736. Ricciardi MR, et al. J Mol Med (Berl), 2012, 90(10), 1133-1144. Pratilas CA, et al. Cancer Res, 2008, 68(22), 9375-9383. Legrier ME, et al. Cancer Res, 2007, 67(23), 11300-11308. Barrett SD, et al. Bioorg Med Chem Lett, 2008, 18(24), 6501-6504.

Write a review

Note: HTML is not translated!
    Bad           Good
Continue

About HDH PHARMA

At HDH Pharma, we are committed to offering our clients the highest quality research services with the most convenient and effective communications from both US and Indian operations. Clients in the Americas and Europe can pick up the phone and speak directly with our scientists in the US. Clients in Asia can receive the same rapid response from our scientists in India. HDH’s hybrid operation is designed with our client’s operational needs in mind.


Information

Extras

My Account

Powered By Nsoft Solutions
HDH PHARMA © 2024